Cell Therapeutics Appoints New Chief Medical Officer Sacramento Bee ... CTI's ongoing randomized controlled phase 3 clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have relapsed after one ... |
Cell Therapeutics Appoints New Chief Medical Officer Sacramento Bee ... CTI's ongoing randomized controlled phase 3 clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have relapsed after one ... |